DOS Kongressen 2014 ·
109
Survival of osteosarcoma patients diagnosed in East
Denmark and treated at Rigshospitalet from 2000-
2010.
Andrea Thorn, Søren Daugaard, Michael Mørk Petersen
Musculoskeletal Tumor Section, Department of Orthopedic Surgery,
Rigshospitalet, University of Copenhagen, Denmark; Department of Pathology,
Rigshospitalet, University of Copenhagen, Denmark
Background:
Osteosarcoma is the most common histological type of bone sar-
comas.
Purpose / Aim of Study:
To examine the overall survival for all osteosarcoma
patients diagnosed in East Denmark and treated at Rigshospitalet from 2000-
2010.
Materials and Methods:
All patients diagnosed with a high-malignant os-
teosarcoma at the Department of Pathology, Rigshospitalet during the years
2000-2010 were identified (n=86). Sixteen patients were excluded because
it was consultation biopsies from other hospitals and 9 patients were excluded
because the diagnosis was later changed (chondrosarcoma/giant cell sarcoma/
osteoblastoma/myeloma/ desmoid fibromatose = 3/1/1/1/1), or was from
before 2000 (n=2). A total of 61 patients (mean age 31 (6-88) years, F/
M=34/27) were then analyzed for survival. Survival data were obtained from
the CPR register. Statistics: Kaplan Meier survival analysis and log-rank test.
Findings / Results:
The probability of 5 and 10-year survival for all patients
(n=61) was 57% and 52% years respectively. The probability of survival in
young individuals (age ≤20 years) was not different from patients aged >20
years (p=0.14) and no difference between sexes (p= 0.19) was found. In pa-
tients treated with preoperative chemotherapy (n=46) the survival was higher
(p=0.002), if the degree of tumor cell necrosis was ≥90%. Both the probability
of 5 and 10 years survival in patients with ≥90% necrosis (n=20) was 90%,
while in patients with <90% necrosis (n=26) survival was 46% and 41% re-
spectively.
Conclusions:
The overall survival for patients with high- malignant osteosar-
coma in East Denmark is consistent with the international average overall sur-
vival for this patient group.
56.
